The acquisition brings together two of healthcare's most installed and trusted platforms

这次收购将医疗保健领域中安装最广泛且最受信赖的两个平台整合在一起。

NASHVILLE, Tenn. and LEXINGTON, Ky.

田纳西州纳什维尔和肯塔基州列克星敦

,

，

April 28, 2026

2026年4月28日

/PRNewswire/ -- Azra AI, the leading end-to-end enterprise platform for incidental findings and oncology workflow automation, today announced the acquisition of Thynk Health, the specialized leader of lung cancer screening and incidental findings management. The deal unites two of healthcare's most trusted names in imaging-driven care coordination, with a shared goal: ensuring that no patient falls through the cracks between detection, diagnosis, and treatment..

/PRNewswire/ -- Azra AI，领先的端到端企业平台，专注于偶发性发现和肿瘤工作流程自动化，今天宣布收购Thynk Health，该公司是肺癌筛查和偶发性发现管理的专门领导者。此次交易将医疗领域中两个最受信赖的影像驱动护理协调领域的佼佼者联合在一起，共同目标是：确保在检测、诊断和治疗之间没有任何患者被遗漏。

The combined Azra AI and Thynk Health platforms are already deployed across hundreds of hospitals and represent the largest install base in its market segment, including five of the top ten healthcare systems in the United States.  Currently processing well over half a billion clinical reports and messages annually in real time — at the scale and reliability that health systems can trust — the combination of these two platforms further strengthens their leadership position, which translates directly into fewer missed findings, faster follow-up, and stronger patient retention across the enterprise. .

结合的Azra AI和Thynk Health平台已经部署在数百家医院，代表了其市场领域中最大的安装基础，包括美国十大医疗系统中的五个。目前每年实时处理超过五亿份临床报告和信息，在健康系统可以信赖的规模和可靠性下运行——这两个平台的结合进一步巩固了它们的领导地位，直接转化为更少的漏诊、更快的跟进以及整个企业更强的患者留存率。

A Platform Built for the Full Continuum

一个为完整连续体而构建的平台

Azra AI's end-to-end platform supports patients seamlessly from initial suspicion through treatment and survivorship — bridging a deep gap that traditional EHRs and point solutions were never designed to address. At its core, Azra's Clinical Patient Data Layer converts fragmented clinical data into structured, actionable workflows, keeping care moving across radiology, pathology, cardiology, emergency departments and other service lines.  Azra's end-to-end platform includes all incidental findings (radiology), cancer patient ID (pathology), patient navigation and care coordination, registry case-finding and abstraction, multi-disciplinary meeting / tumor board, clinical trials matching, and real-time reporting and analytics  — reducing handoff failures, closing care gaps, and ensuring the right action happens at the right moment in every patient's journey..

Azra AI 的端到端平台无缝支持患者从最初怀疑到治疗和生存的整个过程，弥合了传统电子健康记录（EHR）和单点解决方案从未设计解决的深层差距。在核心层面，Azra 的临床患者数据层将分散的临床数据转化为结构化、可操作的工作流程，推动放射科、病理科、心脏科、急诊科及其他服务线之间的护理流动。Azra 的端到端平台涵盖所有偶然发现（放射学）、癌症患者识别（病理学）、患者导航与护理协调、登记病例查找与抽象、多学科会议/肿瘤委员会、临床试验匹配以及实时报告和分析——减少交接失败、填补护理空白，并确保在每位患者的旅程中于正确的时间采取正确的行动。

Thynk Health deepens that foundation where the stakes are highest. As one of the recognized leaders in lung cancer screening and lung incidental findings management, Thynk specializes in the critical window between an imaging finding and a confirmed diagnosis — the moment where follow-up delays most often translate into later-stage disease and worse outcomes..

Thynk Health 在风险最高的领域深化了这一基础。作为肺部癌症筛查和肺部偶发性发现管理的公认领导者之一，Thynk 专注于从影像学发现到确诊之间的关键窗口期——此时随访的延误往往会导致疾病进入更晚期并产生更差的结果。

Health systems already using Thynk Health's lung cancer screening and incidental findings technology will now have access to Azra AI's full platform, giving them a comprehensive, enterprise-wide AI platform strategy.  For existing Azra clients, the combination brings together the best capabilities from both platforms, creating an even more powerful and unified solution for lung cancer screening, incidental findings management, and the full longitudinal patient journey — all within a single, trusted platform..

已经使用 Thynk Health 的肺癌筛查和偶然发现技术的医疗系统现在可以访问 Azra AI 的完整平台，从而获得一个全面的企业级 AI 平台战略。对于现有的 Azra 客户，这种结合融合了两个平台的最佳功能，为肺癌筛查、偶然发现管理以及完整的患者纵向旅程提供了一个更强大且统一的解决方案——全部在一个可信赖的单一平台内实现。

'Health systems are moving beyond fragmented tools and toward true enterprise-wide intelligence platforms,'

“医疗系统正在超越碎片化的工具，朝着真正全企业范围的智能平台迈进。”

said John Marshall, CEO of Azra AI

约翰·马歇尔说道，他是Azra AI的首席执行官。

. 'EHRs were not built for this level of complexity, especially when it comes to delivering the specialized clinical workflows that turn a finding into a follow-up and a follow-up into a life saved.  At the same time, disconnected point solutions further exacerbate the problem by creating fragmentation, limiting scale, and widening the gaps in patient care.

“电子健康记录系统并非为这种复杂程度而构建，特别是在提供将发现转化为后续行动、将后续行动转化为挽救生命的专门临床工作流程时。同时，互不连接的点状解决方案通过造成碎片化、限制规模以及扩大患者护理中的缺口，进一步加剧了这一问题。”

The future of care is not just managing patients once disease is suspected — it's identifying patients earlier, often before symptoms appear. Azra was built from day one to be something fundamentally different — by leveraging discrete clinical data across the enterprise, we can surface high-risk, asymptomatic patients and accelerate diagnosis of life-threatening conditions.

护理的未来不仅仅是管理疑似患病的患者——而是更早识别患者，通常是在症状出现之前。Azra从一开始就旨在实现根本性的不同——通过利用整个企业的离散临床数据，我们可以发现高风险、无症状的患者，并加速对危及生命的疾病的诊断。

That requires an AI platform built for continuous, longitudinal patient journeys and complex workflows that ensures no patient will fall through the cracks.  This combination with Thynk Health, and their amazing people and technology, accelerates our mission of saving lives every day. The platform we have built is extraordinary, and the excitement inside our two organizations is incredible.'.

这需要一个为持续、纵向的患者旅程和复杂工作流程而构建的 AI 平台，以确保没有患者会被遗漏。与 Thynk Health 及其出色的人才和技术相结合，加速了我们每天拯救生命的使命。我们所构建的平台非常卓越，我们两家公司内部的兴奋之情难以言表。

'Too many important imaging findings never lead to action — a missed follow-up, a gap in communication, and a patient's early-stage diagnosis becomes a late-stage one,'

“太多重要的影像学发现从未导致行动——跟进遗漏、沟通空白，患者的早期诊断变成了晚期诊断。”

said Daniel Weeks, CEO of Thynk Health

Thynk Health首席执行官丹尼尔·威克斯表示

. 'That's the problem Thynk was built to solve. Joining Azra gives us the platform depth and reach to deliver continuous, coordinated care with highly actionable data at vast scale across entire health system populations, not just individual programs.  Azra provides an immediate enterprise-wide clinical strategy for health systems' most critical service lines with one platform that spans across the entire longitudinal patient journey — from suspicion past survivorship.

“这就是Thynk旨在解决的问题。加入Azra为我们提供了平台的深度和广度，使我们能够以大规模的可操作数据，在整个健康系统群体中而不仅仅是单个个体项目中提供持续且协调的护理。Azra为健康系统最关键的服务线提供了即时的企业级临床战略，使用一个贯穿患者整个纵向旅程的平台——从怀疑阶段一直到生存期后。”

Add to that Azra's suite of hands-on clinical services — Navigation, Case Finding, MDM/Tumor Board Coordination, and Strategic Program Execution — and health systems have something no point solution or EHR can offer: a partner that runs alongside them, not just a tool they have to operate themselves.

再加上Azra的一系列实践性临床服务——导航、病例查找、MDM/肿瘤委员会协调以及战略项目执行——医疗系统拥有了任何单点解决方案或电子健康记录（EHR）都无法提供的东西：一个与他们并肩前行的合作伙伴，而不仅仅是一个需要自己操作的工具。

There is simply nothing else like it on the market — one platform, one partner, one mission. We could not be happier with the outcome.'.

市场上根本没有其他类似的产品——一个平台，一个合作伙伴，一个使命。我们对结果非常满意。

John Marshall will continue as CEO of the combined organization. Daniel Weeks, formerly CEO of Thynk Health, will assume the role of Chief Operating Officer at Azra AI. Both companies will continue supporting existing customer deployments throughout the integration process, with no disruption to current contracts or workflows.

约翰·马歇尔将继续担任合并后组织的首席执行官。丹尼尔·威克斯，曾任Thynk Health首席执行官，将担任Azra AI的首席运营官。两家公司将在整合过程中继续支持现有的客户部署，当前合同或工作流程不会受到任何中断。

The financial terms of the acquisition were not disclosed..

收购的财务条款未被披露。

About Azra AI

关于Azra AI

Azra AI is a healthcare enterprise platform that operationalizes underutilized data to optimize and orchestrate care and clinical trial pathways — ensuring patients receive immediate, coordinated care within their health system, increasing patient retention and outcomes, and making patient care visible through actionable real-time reporting.

Azra AI 是一个医疗企业平台，利用未被充分利用的数据来优化和协调护理及临床试验路径 —— 确保患者在其医疗系统内获得即时、协调的护理，提高患者的留治率和治疗效果，并通过可操作的实时报告使患者护理可见。

By combining advanced agentic AI, multimodal data integration, and workflow automation, Azra transforms fragmented clinical data into actionable intelligence—powering solutions across lung and breast cancer screening, all incidental findings, multi-disciplinary meetings, enterprise patient management / care coordination, clinical trial matching, ED discharge, and robust reporting and analytics..

通过结合先进的代理人工智能、多模态数据集成和工作流程自动化，Azra 将碎片化的临床数据转化为可操作的情报——为肺癌和乳腺癌筛查、所有偶发性发现、多学科会议、企业患者管理/护理协调、临床试验匹配、急诊出院以及强大的报告和分析等解决方案提供支持。

Azra's ability to unify these capabilities within a single platform enables health systems to identify patients earlier, coordinate care longitudinally, and eliminate gaps across the continuum. Deployed across hundreds of leading health systems, Azra's platform reduces time to treatment, which delivers measurable improvements in patient outcomes, operational efficiency, and ROI at scale. .

Azra能够在一个平台上整合这些功能，使医疗系统可以更早地识别患者，纵向协调护理，并消除整个连续过程中的缺口。Azra的平台已部署在数百个领先的医疗系统中，缩短了治疗时间，从而大规模地提供了患者结果、运营效率和投资回报率方面可衡量的改善。

Learn more at our new website:

请访问我们的新网站了解更多信息：

www.azra-ai.com

www.azra-ai.com

Media Contact:

媒体联系人：

John Marshall,

约翰·马歇尔，

CEO,

首席执行官，

[email protected]

电子邮件地址

SOURCE Azra AI

来源：Azra AI

21

21

%

%

more press release views with

更多新闻发布视图与

Request a Demo

请求演示